DKBmed Radio
DKBmed
Podcast
Episodes
Listen, download, subscribe
Newer NNRTI Agents in Clinical Practice
Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Rilpivirine, in combination with cabotegravir, provides a long-acting injectable option for both treatment and PrEP. But what risk factors have been associated with virologic failure? Doravirine appears to provide a favorable impact on weight and lipid outcomes, but with a lower genetic barrier to resistance. Which patients is it right for and in which ones should it be avoided? Join us as we discuss Newer NNRTI Agents in Clinical Practice with Dr. Darcy Wooten from the Division of Infectious Disease at the University of California, San Diego, in this issue of eHIV Review. Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.
DKBmed Radio RSS Feed
